{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:38:44Z","timestamp":1788385124447,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T00:00:00Z","timestamp":1493942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Comorbidity impacts survival in B\u2010cell lymphoma patients, but the influence in peripheral T\u2010cell lymphomas (PTCLs) has been little studied. To investigate the impact of comorbidity on outcome in PTCL, we identified adult patients with newly diagnosed PTCL from 2000 to 2009 in the Swedish Lymphoma Registry. Data on comorbidity at diagnosis were retrospectively collected according to the Charlson Comorbidity Index (CCI). Comorbid conditions were present in 263 out of 694 (38%) patients. A CCI score of \u22652 was associated with inferior overall survival (OS) (hazard ratio [HR] 1.63, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) and progression\u2010free survival (HR 1.54, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) in multivariate analysis. In patients undergoing front\u2010line autologous stem cell transplantation (auto SCT), CCI &gt;0 was associated with inferior OS (HR 2.40, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.013). Chemotherapy regimens were classified as curative or low\u2010intensity treatments. Among patients aged \u226575\u00a0years (n\u00a0=\u00a0214), low\u2010intensity and curative treatment groups had similar OS (HR 0.8, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.6), also when adjusted for CCI. In summary, our results demonstrate CCI to be independently associated with survival in PTCLs. Even limited comorbidity impacted survival after front\u2010line auto SCT, which needs to be considered in treatment decisions. Intensive anthracycline\u2010based chemotherapy in elderly PTCL patients might be of limited benefit.<\/jats:p>","DOI":"10.1002\/hon.2428","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T08:02:42Z","timestamp":1493971362000},"page":"159-165","source":"Crossref","is-referenced-by-count":11,"title":["Impact of comorbidity on survival in peripheral T\u2010cell lymphomas: A Swedish Lymphoma Registry study"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9034-5966","authenticated-orcid":false,"given":"Fredrik","family":"Ellin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Kalmar County Hospital  Kalmar Sweden"},{"name":"Department of Clinical Sciences Lund Section for oncology and pathology, Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund Section for oncology and pathology, Lund University  Lund Sweden"},{"name":"Department of Oncology Skane University Hospital  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"T\u00f6rnqvist","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund Section for oncology and pathology, Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Brudin","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology Kalmar County Hospital  Kalmar Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Relander","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund Section for oncology and pathology, Lund University  Lund Sweden"},{"name":"Department of Oncology Skane University Hospital  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05508.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.01.010"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-010-0973-x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12765"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.05.002"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.188"},{"key":"e_1_2_9_8_1","first-page":"1795","article-title":"Comorbidity as an independent prognostic factor in elderly patients with peripheral T\u2010cell lymphoma","volume":"9","author":"Zhao H","year":"2016","journal-title":"Onco Targets Ther"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu443"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.040"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2441"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_9_17_1","volume-title":"WHO classification of Tumours of Haematopoetic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.790968"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3238"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2095"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2015.01.003"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13619"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2428","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:55:46Z","timestamp":1695552946000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/hon.2428"],"URL":"https:\/\/doi.org\/10.1002\/hon.2428","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,5]]}}}